Abivax SA Schedule 13D activist filings

Sofinnova Crossover I SLP and associated individuals have amended their Schedule 13D filing to report the sale of Abivax S.A. American Depositary Shares and Ordinary Shares.

Sofinnova Crossover I SLP and associated parties have filed an amendment to their Schedule 13D, disclosing changes in beneficial ownership and a transaction involving royalty certificates.

Sofinnova Crossover I SLP and related entities have reduced their beneficial ownership in Abivax S.A. by selling approximately 1 million American Depositary Shares (ADS) across two days in January 2026.

Sofinnova Crossover I SLP and related entities have reduced their beneficial ownership in Abivax SA to approximately 5.6% of outstanding ordinary shares through recent ADS sales.

Sofinnova Crossover I SLP and its affiliates have increased their beneficial ownership in Abivax SA to 11.4% of voting rights through a $17.28 million acquisition of American Depositary Shares in a recent public offering.

Sofinnova Crossover I SLP and its affiliates have increased their voting rights in Abivax SA to 11.0% due to the automatic application of French double voting rights for long-held shares.